Intravascular Lithotripsy-Assisted Transfemoral Transcatheter Aortic Valve Implantation

요약

Transcatheter aortic valve implantation (TAVI) has been shown to generate the best clinical outcomes when performed by the percutaneous transfemoral approach. Intravascular lithotripsy (IVL) can facilitate a transfemoral process in patients with calcified iliofemoral vascular disease and borderline intraluminal diameters. The present protocol describes IVL-assisted transfemoral TAVI.

초록

During the last decade, transcatheter aortic valve implantation (TAVI) has evolved as a well-established therapy for aging patients suffering from symptomatic severe aortic valve stenosis. This is also reflected in the recently updated international guidelines on managing patients with valvular heart disease. A transfemoral (TF) TAVI approach has proven superior to alternative access strategies. With the introduction of intravascular lithotripsy (IVL), patients with calcified iliofemoral vascular disease and borderline intraluminal diameters have also become candidates for percutaneous TF-TAVI. Moreover, IVL reduces the risk of major vascular complications by modifying the superficial and deep vascular calcium, thereby changing the vessel compliance and controlling luminal expansion. In this way, IVL has shown to safely facilitate TF delivery of TAVI devices in patients with calcified peripheral artery disease. The present article aims to provide a detailed step-by-step description on how to perform IVL-assisted TF-TAVI safely and efficiently. Furthermore, a literature review on the outcomes obtained with this technology is included, along with a concise discussion on this unique TAVI approach.

서문

Transcatheter aortic valve implantation (TAVI) has proven to be a valuable therapy for elderly patients suffering from symptomatic severe aortic valve stenosis (AS) across all surgical risk categories^1,2. The data and outcomes are most convincing for those patients in whom the TAVI procedure can be performed by transfemoral (TF) approach. TAVI by alternative access, such as transsubclavian, transaxillary, transcarotid, transcaval, and transapical access, can also be considered. However, the complication rates reported for TAVI by alternative access are higher than TF-TAVI^3,4. This is also reflected in the most recent EU and US guidelines on managing patients with valvular heart disease⁵, in which there is a prominent role for TF-TAVI as a treatment option for patients with symptomatic severe AS.

Although there is consensus that TF-TAVI should be the default strategy for patients with proper iliofemoral access⁵, peripheral arterial disease (PAD) is not uncommon in patients planned for TAVI, given their advanced age and often multiple co-morbidities⁶. There has been a rapid technological evolution in the TAVI field over the past few years, resulting in TAVI devices with lower insertion profiles and more flexible delivery systems. Also, increased operator experience has increased the use of a fully percutaneous TF-TAVI approach. Nowadays, more than 90% of TAVI cases are performed in this way in most advanced TAVI centres⁷.

Still, a group of patients (5%-10%) remain good candidates for TAVI but suffer from severely calcified PAD. For many of these patients, the introduction of peripheral intravascular lithotripsy (IVL) has opened up the possibility to be treated by TF-TAVI. When using IVL, one generates sonic pressure waves using miniaturized lithotripters emitters integrated within a balloon. A steam bubble is created inside the balloon that rapidly expands and collapses by delivering electrical energy. This generates sonic pressure waves, similar in their waveform to those used during extracorporeal lithotripsy of nephrolithiasis. These waves travel through the vessel with a positive peak pressure of around 50 atm, thereby cracking and modifying both the superficial and deep vascular calcium, ultimately changing the vessel compliance and allowing for controlled luminal expansion^8,9,10 (Figure 1). In this way, IVL has been shown to facilitate TF delivery of TAVI devices in patients with calcified PAD in a safe manner^11,10,13. These IVL balloons are available in different diameters ranging between 3.5 mm-7 mm with a length of 60 mm.

The present article aims to provide a detailed description of performing IVL-assisted TF-TAVI safely and efficiently. Furthermore, a literature review on the outcomes obtained with this technology is included, along with a concise discussion on this new TAVI approach.

Patients (male/female) with a diseased iliofemoral anatomy corresponding to the following criteria could be suitable for IVL-assisted TF-TAVI (Figure 2): (1) Iliofemoral vascular disease with a lesion length of <20 mm and a calcium arc of ±270°, having a minimal lumen diameter of >3.0 mm, (2) iliofemoral vascular disease with a lesion length of <20 mm and calcium of arc ±360°, having a minimal lumen diameter of >4.0 mm, (3) iliofemoral vascular disease with a lesion length of >20 mm and a calcium arc of ±270°, having a minimal lumen diameter of >3.5 mm, and (4) iliofemoral vascular disease with a lesion length of >20 mm and calcium of arc ±360°, possessing a minimal lumen diameter of >4.5 mm. These recommendations are based upon expert opinion and local practice.

프로토콜

The protocol is approved by the human research ethics committee of Copenhagen University Hospital, and the studies are conducted following the guidelines of the said ethics committee. Following local policies, all patients gave informed consent for the TAVI procedure, cardiac CT scanning, and anonymous data for research.

1. Preprocedural planning

1. Inspect the aorta-iliofemoral vessels ranging from the aortic valve, over the aortic arch, down to the common femoral artery (CFA) and the femoral bifurcation. For an accurate evaluation, perform a dedicated computed tomography (CT) angiography¹⁴ and make an angiography-based three-dimensional (3D) reconstruction using dedicated software¹⁵ (see Table of Materials).
   1. Visually assess the degree of vessel tortuosity.
   2. Visually assess the degree and amount of vessel calcification (arc, morphology, etc.)¹⁶. Pay specific attention to calcified spots with a calcified circumference of >270°.
   3. Measure the minimal luminal diameter (MLD), maximal luminal diameter, and mean luminal diameter at the site of the most critical calcifications and stenoses¹⁶.
   4. Decide upon the feasibility of a TF approach for TAVI. Assess the need for and benefit of an IVL-assisted TF approach. Take into account the recommendations provided in Figure 2.
   5. Determine the region of interest for possible IVL-treatment: iliac bifurcation, common iliac artery and/or external iliac artery.
   6. Determine the preferred TAVI access/puncture site referring to the preprocedural CT angiography; this concerns the femoral bifurcation and femur head.
   7. Decide upon the diameter and length of (un)covered stents if this is needed in vascular bailout situations.

2. Obtaining vascular access

1. Apply local anesthesia by injecting ~10-20 mL of Xylocaine (10 mg/mL) solution in the skin and subcutaneous tissue at the preferred puncture site for TAVI. Confirm the effect of anesthesia by testing skin sensitivity with a needle.
2. Perform an echo-guided puncture of the CFA and insert a 0.035" guidewire (see Table of Materials).
   NOTE: Avoid a CFA puncture too close to the femoral bifurcation as this may complicate and compromise the option for bailout stenting of the CFA in case of vascular closure device failure. Verify this by fluoroscopy.
3. Make a skin incision of 2-3 cm and insert a 7 F-8 F dilator (see Table of Materials) over the wire.
4. Keep the 0.035" guidewire into the artery and remove the 7 F-8 F dilator. Decide on vascular closure strategy (e.g., suture-based, plug-based closure, etc.) and perform pre-closure maneuvers if necessary.
5. Insert the 7 F-8 F sheath (see Table of Materials) over the wire.
6. Administer intravenous heparin according to the local protocol (e.g., 100 IU/kg).

3. Usage and positioning of a safety wire

1. In a percutaneous intervention at an IVL-treated site, position a safety wire across the main access site and a wire in the abdominal aorta. Strictly keep this wire even after retraction of the TAVI system and the large bore insertion sheath.
   NOTE: If the main TAVI access site is not diseased, there is no absolute need to position a safety wire across the main puncture site.
2. In case of vascular disease at the TAVI access site, consider a safety wire crossing the main puncture site, either introduced by a contralateral (e.g., through a 6 F-8 F long sheath), lower ipsilateral, or transradial secondary arterial access. Use this safety wire to treat vascular complications at the puncture and/or IVL-treated sites.
3. Choose a 0.018" safety wire (which is stiff enough, see Table of Materials) to deliver vascular balloons and/or stents, if needed, but with a floppy, non-traumatic tip. Keep this safety wire in place during the entire TAVI procedure until confirmation of good vascular closure.

4. IVL system set-up

1. Introduce a 0.014" guidewire, preferably with extra supportive characteristics, into the 7F-8F sheath at the main TAVI access site. Do not push this wire across the aortic arch.
2. Turn on the IVL generator and get the connector cable (see Table of Materials) connected to it.
3. Choose a 110 cm long IVL catheter with a balloon length of 60 mm and diameters ranging from 3.5-8 mm on an over-the-wire (OTW) system (see Table of Materials).
   NOTE: There are three ports on the distal end of the catheter: one to connect the IVL connector, one for inflating and deflating the balloon, and one that fits the 0.014" guidewire.
4. Prepare the IVL catheter/balloon following the steps below.
   1. Aspirate 5 mL of a 50% contrast (see Table of Materials) and 50% saline mixture into a 20 mL syringe. Connect to the inflation/deflation port of the balloon catheter.
   2. Pull-on the syringe to aspirate air and replace this air inside the catheter with the fluid mixture in the syringe. Repeat at least three times.
5. Fill an indeflator device (see Table of Materials) with 50% saline/50% contrast medium. Disconnect the 20 mL syringe and connect the indeflator to the inflation port of the IVL catheter with a three-way stopcock in an intermediate position, ensuring no air is introduced into the system.
6. Flush the guidewire exit port at the distal end of the IVL catheter with a saline solution.
7. Wrap the connector cable in a sterile cover.
8. Connect the IVL catheter in a sterile fashion to the connector cable. Wrap some adhesive tape or a rubber band around the connection between the sterile catheter and the sterile cover to prevent it from sliding.
9. Push the therapy button on the IVL generator. The light will switch from orange to green.
   NOTE: Do not press the therapy button unless the balloon is filled with 50% saline/50% contrast medium (otherwise, it risks damaging the lithotripsy emitters). The IVL system is now ready for use (Figure 1).

5. IVL treatment

1. Make the balloon and shaft of the IVL catheter wet before insertion to activate the hydrophilic coating.
2. Insert the IVL catheter over the wire (OTW) into the 7 F-8 F sheath (main access site).
3. Use fluoroscopy to position the marker bands at the region of interest.
4. Inflate the IVL balloon to 4 atm. Document correct positioning and inflation using fluoroscopy. Ensure no air visible in the inflated balloon.
5. Press and hold the activation button on the connector handle. Hold for 10 s to apply one cycle of 30 IVL pulses. Audible clicks and light flashes will confirm that the therapy is delivered.
6. At the end of the 30 IVL pulses, increase the inflation of the IVL balloon to 6 atm. Hold this pressure for 4 s.
7. Deflate the balloon and keep the negative pressure for 30 s to ensure it is empty. Repeat this action two more times.
8. Repeat steps 5.3-5.7 for a maximum amount of 10 cycles with 30 IVL pulses (300 pulses in total).
9. Confirm that the balloon is fully deflated before removing the IVL catheter.
10. Exchange the 0.014" guidewire for a 0.018"-0.035" guidewire, depending on further planning (steps 5.11-5.12).
11. If needed, perform additional percutaneous transluminal angioplasty (PTA) with a non-compliant balloon (e.g., 6-8 mm).
12. Ensure that a 0.035" stiff guidewire is in place before inserting the large bore TAVI introducer sheath into the main access site.
13. Continue the TAVI procedure, as usual.

6. Vascular closure after TAVI

1. Before removing the insertion sheath, check the position of the safety wire. Always have a bailout option for percutaneous intervention with balloons and/or (un)covered stents in mind and ready in the cath lab.
2. Perform vascular closure employing a suture-or plug-based vascular closure device (see Table of Materials).
3. Asses the vascular closure with contrast injection, either from the secondary access site or through a 6 F sheath which replaced the large bore insertion sheath.
   NOTE: A digital subtraction angiography (DSA) can be helpful in better identifying possible vascular complications¹⁷. Select and use the DSA mode on your module and ask the patient to hold their breath while performing the recording.
4. If a vascular complication occurs, treat accordingly. For example, place a covered stent in case of significant extravasation and an uncovered stent in a spiral dissection, etc.

결과

IVL treatment (Figure 1) of calcified PAD was first investigated in the DISRUPT-PAD European pre-market study¹⁸. The study showed an acute increase in vessel diameter in 35 patients following peripheral IVL treatment at the cost of only minimal vessel injury. The multi-center DISRUPT-PAD II trial¹⁹ confirmed these findings in 60 patients. DISRUPT PAD III²⁰ was designed as a real-world, prospective, multi-center study in ...

토론

Since the introduction of TAVI as a treatment option for patients with severe symptomatic AS, studies and registries have demonstrated that TAVI by TF approach generates better procedural success and lower complication rates^3,4,23. As a result, most centers nowadays seek to perform most of their TAVI procedures by percutaneous TF approach²³.

The introduction of IVL as a new too...

자료

Name	Company	Catalog Number	Comments
0.014” guidewire	Floppy II Extra Support Guide Wire, Abbott, USA	22299M
0.035’’ stiff guidewire	Amplatz superstiff j-tip 7 cm floppy, Boston Scientific, USA	M001465020
20 mL syringe
6 F or 8 F femoral sheat	Radifocus Introducer II, Terumo	RS*B70N10MRD and RS*B80N10MRD
6-8 F Arrow sheat 35 cm- if contralateral access	Teleflex	CL07635 and CL07835
Arterial puncture needle	Percutaneous entry thinwall needle, Cook Medical	SDN18-18-7.0
Contrast solution	Visipaque 350, GE Healthcare
CT angiography-based 3D reconstruction dedicated software	3mensio, Pie Medical, The Netherlands
Diagnostic catheter	6F IMA diagnostic catheter, Cordis	534-6605
Echo probe sterile cover	CIV-flex transducer cover, CIVCO	610-1212
Indeflator device (20 mL)	Everest 30, Medtronic	AC3200
IVL Connector Cable	Shockwave medical	IVLCC
IVL generator	Shockwave medical	IVLGCC
Local anesthetic	Xylocain 10 mg/mL, Aspen
Non-compliant balloon	Z-MED II balloon 6 to 8 mm, Numed Canada inc.	PDZ622
Safety wire	0.018’’ Platinum Plus guidewire, Boston Scientific, USA	M0014666050
Shockwave M5/M5+ catheter (7 mm-8 mm diameter)	Shockwave medical	M5IVL7060 - M5PIVL7060 - M5PIVL8060
Standard J-wire	angiodyn guide wire j-tip, B. Braun	5050200
Sterile cover for shockwave connector cable	camera drape, Mönlycke health care
Three-way stopcock
Unfractionated heparin	10 mL vials of 1000 IE/mL, Amgros I/S
Vascular closure device	Perclose Prostyle device, Abbott, USA	12773-02
Vascular echo probe
	Manta VCD, Essential Medical, USA	2156NE, 2115NE